STING1 and neoplasm: Furthermore, in vivo experiments demonstrated that the loss of ERRFI1, a pivotal gene within the STING signature, significantly enhanced antitumor immunity and exhibited a synergistic effect with α-PD1 therapy to promote tumor control.